News | December 19, 2025
Lupin signs exclusive licensing pact with Neopharmed for Plasil in Philippines and Brazil
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Subscribe To Our Newsletter & Stay Updated
